Pentoxifylline treatment and penile calcifications in men with Peyronie's disease

James F. Smith, Alan W. Shindel, Yun Ching Huang, Raul I. Clavijo, Lawrence Flechner, Benjamin N. Breyer, Michael L. Eisenberg, Tom F. Lue

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This retrospective cohort study from a single clinical practice enrolled patients with evidence of calcified Peyronie's disease (PD) plaques detected on penile ultrasound at the time of initial presentation. The primary objective was to describe the effect of pentoxifylline (PTX) treatment on subtunical calcifications in men with PD. A PD-specific questionnaire was administered and sonographic evaluations were performed at baseline and follow-up visits. Descriptive statistics and Ï ‡ 2 analysis were used to characterize the effect of PTX on calcified tunical plaques. In all, 71 men (mean age: 51.9 years) with PD and sonographic evidence of calcification were identified. Of them, 62 of these men were treated with PTX for a mean duration of 1 year, and nine with vitamin E or no treatment. Improvement or stabilization in calcium burden at follow-up was noted in 57 (91.9%) of men treated with PTX versus four (44.4%) of those not treated with PTX (P0.001). PTX users were much less likely to have a subjective worsening of their clinical condition (25.0% versus 78.3%, P0.002). Treatment with PTX appeared to stabilize or reduce calcium content in PD plaques. A randomized controlled trial is warranted to further explore this effect.

Original languageEnglish (US)
Pages (from-to)322-325
Number of pages4
JournalAsian Journal of Andrology
Volume13
Issue number2
DOIs
StatePublished - Mar 2011

Fingerprint

Penile Induration
Pentoxifylline
Therapeutics
Calcium
Vitamin E
Cohort Studies
Randomized Controlled Trials
Retrospective Studies

Keywords

  • penile calcifications
  • pentoxifylline
  • Peyronie's disease
  • treatment

ASJC Scopus subject areas

  • Urology

Cite this

Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. / Smith, James F.; Shindel, Alan W.; Huang, Yun Ching; Clavijo, Raul I.; Flechner, Lawrence; Breyer, Benjamin N.; Eisenberg, Michael L.; Lue, Tom F.

In: Asian Journal of Andrology, Vol. 13, No. 2, 03.2011, p. 322-325.

Research output: Contribution to journalArticle

Smith, James F. ; Shindel, Alan W. ; Huang, Yun Ching ; Clavijo, Raul I. ; Flechner, Lawrence ; Breyer, Benjamin N. ; Eisenberg, Michael L. ; Lue, Tom F. / Pentoxifylline treatment and penile calcifications in men with Peyronie's disease. In: Asian Journal of Andrology. 2011 ; Vol. 13, No. 2. pp. 322-325.
@article{d5afee076b0348eb9ca5893c7b7daac8,
title = "Pentoxifylline treatment and penile calcifications in men with Peyronie's disease",
abstract = "This retrospective cohort study from a single clinical practice enrolled patients with evidence of calcified Peyronie's disease (PD) plaques detected on penile ultrasound at the time of initial presentation. The primary objective was to describe the effect of pentoxifylline (PTX) treatment on subtunical calcifications in men with PD. A PD-specific questionnaire was administered and sonographic evaluations were performed at baseline and follow-up visits. Descriptive statistics and {\"I} ‡ 2 analysis were used to characterize the effect of PTX on calcified tunical plaques. In all, 71 men (mean age: 51.9 years) with PD and sonographic evidence of calcification were identified. Of them, 62 of these men were treated with PTX for a mean duration of 1 year, and nine with vitamin E or no treatment. Improvement or stabilization in calcium burden at follow-up was noted in 57 (91.9{\%}) of men treated with PTX versus four (44.4{\%}) of those not treated with PTX (P0.001). PTX users were much less likely to have a subjective worsening of their clinical condition (25.0{\%} versus 78.3{\%}, P0.002). Treatment with PTX appeared to stabilize or reduce calcium content in PD plaques. A randomized controlled trial is warranted to further explore this effect.",
keywords = "penile calcifications, pentoxifylline, Peyronie's disease, treatment",
author = "Smith, {James F.} and Shindel, {Alan W.} and Huang, {Yun Ching} and Clavijo, {Raul I.} and Lawrence Flechner and Breyer, {Benjamin N.} and Eisenberg, {Michael L.} and Lue, {Tom F.}",
year = "2011",
month = "3",
doi = "10.1038/aja.2010.117",
language = "English (US)",
volume = "13",
pages = "322--325",
journal = "Asian Journal of Andrology",
issn = "1008-682X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Pentoxifylline treatment and penile calcifications in men with Peyronie's disease

AU - Smith, James F.

AU - Shindel, Alan W.

AU - Huang, Yun Ching

AU - Clavijo, Raul I.

AU - Flechner, Lawrence

AU - Breyer, Benjamin N.

AU - Eisenberg, Michael L.

AU - Lue, Tom F.

PY - 2011/3

Y1 - 2011/3

N2 - This retrospective cohort study from a single clinical practice enrolled patients with evidence of calcified Peyronie's disease (PD) plaques detected on penile ultrasound at the time of initial presentation. The primary objective was to describe the effect of pentoxifylline (PTX) treatment on subtunical calcifications in men with PD. A PD-specific questionnaire was administered and sonographic evaluations were performed at baseline and follow-up visits. Descriptive statistics and Ï ‡ 2 analysis were used to characterize the effect of PTX on calcified tunical plaques. In all, 71 men (mean age: 51.9 years) with PD and sonographic evidence of calcification were identified. Of them, 62 of these men were treated with PTX for a mean duration of 1 year, and nine with vitamin E or no treatment. Improvement or stabilization in calcium burden at follow-up was noted in 57 (91.9%) of men treated with PTX versus four (44.4%) of those not treated with PTX (P0.001). PTX users were much less likely to have a subjective worsening of their clinical condition (25.0% versus 78.3%, P0.002). Treatment with PTX appeared to stabilize or reduce calcium content in PD plaques. A randomized controlled trial is warranted to further explore this effect.

AB - This retrospective cohort study from a single clinical practice enrolled patients with evidence of calcified Peyronie's disease (PD) plaques detected on penile ultrasound at the time of initial presentation. The primary objective was to describe the effect of pentoxifylline (PTX) treatment on subtunical calcifications in men with PD. A PD-specific questionnaire was administered and sonographic evaluations were performed at baseline and follow-up visits. Descriptive statistics and Ï ‡ 2 analysis were used to characterize the effect of PTX on calcified tunical plaques. In all, 71 men (mean age: 51.9 years) with PD and sonographic evidence of calcification were identified. Of them, 62 of these men were treated with PTX for a mean duration of 1 year, and nine with vitamin E or no treatment. Improvement or stabilization in calcium burden at follow-up was noted in 57 (91.9%) of men treated with PTX versus four (44.4%) of those not treated with PTX (P0.001). PTX users were much less likely to have a subjective worsening of their clinical condition (25.0% versus 78.3%, P0.002). Treatment with PTX appeared to stabilize or reduce calcium content in PD plaques. A randomized controlled trial is warranted to further explore this effect.

KW - penile calcifications

KW - pentoxifylline

KW - Peyronie's disease

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=79952402829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952402829&partnerID=8YFLogxK

U2 - 10.1038/aja.2010.117

DO - 10.1038/aja.2010.117

M3 - Article

C2 - 21102473

AN - SCOPUS:79952402829

VL - 13

SP - 322

EP - 325

JO - Asian Journal of Andrology

JF - Asian Journal of Andrology

SN - 1008-682X

IS - 2

ER -